InvestorWire NewsRoom


InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Making Significant Strides to Advance Cellular Therapy Programs
September 22, 2023

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Making Significant Strides to Advance Cellular Therapy Programs

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. “The company is guided by the mission to advance cell-based product candidates into pivotal phase 3 trials, with the goal of attaining regulatory approvals and subsequently commercializing the product. Longeveron has so far made significant strides in line with this mission,” reads a recent article that discussed attendance by the company’s CEO Wa’el Hashad and EVP and CFO Lisa Locklear at the recent 25th Annual H.C. Wainwright Global Investment Conference. At the event, they discussed the company’s investment strategies and clinical trial progress. “The programs and clinical trials are currently anchored in the company’s lead investigational therapeutic candidate, a cellular therapy called Lomecel-B(TM). Lomecel-B is derived from culture-expanded medicinal signaling cells (“MSCs”) isolated from the bone marrow of healthy young adult donors. Looking ahead, Longeveron is looking to create awareness of these cellular therapy programs, the progress made with its clinical trials, and accompanying positive clinical data at conferences and scientific sessions.”

To view the full article, visit

About Longeveron Inc.

Longeveron is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM) an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B(TM) has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B(TM) through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. Additional information about the company is available at

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).